Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes

American Journal of Gastroenterology

Volumn 100, Issue 6, 2005, Pages 1317-1321

  Chalasani, Naga ^a   Teal, Evgenia ^b   Hall, Stephen D ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIVER ENZYME; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; TRANSAMINASES; TREATMENT OUTCOME;

EID: 21344452562     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41690.x     Document Type: Article

References (23)

1. Meriden T. Progress with thiazolidinediones in the management of Type 2 diabetes mellitus. Clin Ther 2004;26:177-90.
2. Reusch JE, Gadsby R. Thiazolidinedione therapy: The benefits of aggressive and early use in type 2 diabetes. Diabetes Techno Ther 2003;5:685-93.
3. www.drugtopics.com (accessed on 6/23/04).
4. Isley WL. Hepatotoxicity of thiazolidinediones. Expert Opin Drug Safety 2003;2:581-6.
5. Scheen AJ. Hepatotoxicity with thiazolidinediones: Is it a class effect? Drug Safety 2001;24:873-88.
6. Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003;7:369-79.
7. Bonkovsky HL, Azar R, Bird S, et al. Severe cholestatic hepatitis caused by thiazolidinediones: Risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002;47:1632-7.
8. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000;132:118-21.
9. Al-Salman J, Heider A, Kemp D et al. Hepatocellular injury in a patient receiving rosiglitazone: A case report. Ann Intern Med 2000;132:121-4.
10. May LD, Lefkowitch JH, Kram MT et al. Mixed hepatocellular-cholestatic liver injury after proglitazone therapy. Ann Intern Med 2002;136:449-52.
11. Pinto AG, Cummings OW, Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy. [Letter]. Ann Intern Med 2002;137:857.
12. Maeda K. Hepatocellular injury in a patient receiving pioglitazone [Letter]. Ann Intern Med 2001;135:306.
13. Physician Desk Reference (PDR), 58th Edition, 2004.
14. Sanyal AJ, Contos AJ, Sargeant C et al. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis. [Abstract]. Hepatology 2002;26:A382.
15. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
16. Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
17. McDonald CJ, Overhage JM, Tierney WM et al. The Regenstrief Medical Record System : A quarter century experience. Int J Med Inform 1999;54:225-53.
18. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92.
19. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;39:237-42.
20. Senior JR. Regulatory perspective. In Kaplowitz N, DeLeve LD(eds.) Drug Induced Liver Disease. Marcel Dekker, Inc., New York, NY;2003:739-54.
21. Murray MD, Loos B, Tu W et al. Work patterns of ambulatory care pharmacists with access to electronic guideline-based treatment suggestions. Am J Health Syst Pharm 1999;56(3):225-32.
22. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in Type 2 diabetic patients during clinical trials. Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25:815-21.
23. https://dilincentral.dcri.duke.edu, accessed on December 16, 2004.